摘要
目的:通过研究内皮祖细胞(EPC)增殖、迁移、分化及细胞因子的分泌,探讨中-低剂量的阿托伐他汀对急性心肌缺血性损伤患者的外周血EPC的影响。方法:选择急性ST段抬高型心肌梗死(STEMI)患者80例,根据服用阿托伐他汀的剂量不同,随机分为观察组(阿托伐他汀40 mg)和对照组(阿托伐他汀20 mg),每组各40例。采用四唑盐(MTT)比色法、流式细胞术和酶联免疫吸附测定的方法,检测药物治疗前后不同时间点STEMI患者体内循环的EPC细胞数量、增殖能力和细胞因子的分泌。结果:观察组和对照组阿托伐他汀治疗2周内均使EPC明显增殖,迁移能力有较大改变。治疗期间细胞因子的分泌表现为内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、趋化因子4(CXCR4)出现先增加后减少,但沉默调节蛋白1(SIRT1)持续增加。各组数据显示观察组和对照组差异无统计学意义。结论:STEMI患者服用中-低剂量的阿托伐他汀能有效改善EPC的增殖和迁移能力,增加了CXCR4、VEGF、bFGF及SIRT1的表达。
Objective： To explore the impact of middle and low dose atorvastatin on peripheral endothelial progenitor cells （EPCs） in patients with acute myocardial ischemia injury via investigating EPC proliferation, migration, differentiation and secretion of cytokines. Method： A total of 80 patients with acute ST-segment elevation myocardial infarction （STEMI） were randomly divided into 2 groups： Observation group, the patients received atorvastatin 40 mg and Control group, the patients received atorvastatin 20 mg. n=40 in each group. The number of circulating EPC, EPC proliferation ability and the secretion of cytokines before and at different time points after drug therapy were examined by means of MTT, flow cytometry and ELISA. Results： The number of EPC was obviously increased with greatly changed migration ability within 2 weeks atorvastatin treatment in both groups. The secretion of cytokines presented that the contents of VEGF, bFGF, CXCR were elevating first followed by reducing thereafter, while the content of SIRTlwas continuously increasing during the period of treating. The above parameters were similar between 2 groups. Conclusion： Middle and low dose atorvastatin could effectively improve EPC proliferation and migration, increase the exoressions ofCXCR4, VEGF, bFGF and SIRT1 in STEMI Patients.
出处
《中国循环杂志》
CSCD
北大核心
2017年第7期697-700,共4页
Chinese Circulation Journal
关键词
心肌缺血
内皮祖细胞
降血脂药
Myocardial ischemia
Endothelial progenitor cells
Lipid-lowering drug
